Clinical trials: Pembrolizumab
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
Study Purpose and Design:A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 in Combination with Pembrolizumab Injection in Patients with…
- Trial name
- NCT05145907
- Testing
- TJ107 +Pembrolizumab
- Where
- 20 sites in China
- Volunteers
- 133 people
- Sponsor
- TJ Biopharma Co., Ltd.
Bladder Cancer, Gastric Cancer
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies.
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT04383938
- Testing
- APR-246 (eprenetapopt) + Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aprea Therapeutics
Advanced/Metastatic Melanoma
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
This is a Phase 2 study to assess the efficacy, safety, and tolerability of gebasaxturev administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone…
- Trial name
- NCT04152863
- Testing
- Gebasaxturev IV, Gebasaxturev ITu, Pembrolizumab
- Where
- 30 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.
- Trial name
- PemCiGem (NCT02608684)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Cedars-Sinai Medical Center
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
This randomized pilot phase II trial studies the effect of pembrolizumab with or without carboplatin and paclitaxel on immune response in patients with non-small cell lung cancer that has come back or stage IIIB-IV.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02581943
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Wake Forest University Health Sciences
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC)…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT05812807
- Testing
- Pembrolizumab, Patient Observation, Biopsy
- Where
- 846 sites in United States, Canada and 1 more
- Volunteers
- 1,295 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Advanced Melanoma
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor…
- Trial name
- NCT05105100
- Testing
- Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Locally Advanced or Metastatic Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT05205109
- Testing
- ATG-037, KEYTRUDA ®( Pembrolizumab)
- Where
- 7 sites in Australia, China
- Volunteers
- 98 people
- Sponsor
- Antengene Therapeutics Limited
Head and Neck Neoplasms
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and…
- Trial name
- NCT03040999
- Testing
- Pembrolizumab, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 804 people
- Sponsor
- Merck Sharp & Dohme LLC
CD19 Positive, Philadelphia Chromosome Positive
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment.
- Conditions
- CD19 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT03512405
- Testing
- Blinatumomab, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Thymoma and Thymic Carcinoma
Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma
This is an investigational, single arm study.
- Trial name
- NCT04554524
- Testing
- Chemotherapy+Pembrolizumab.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Background: Many cancers of the testicles and urinary tract are rare diseases; these are diseases that affect less than 200,000 people in the United States. It can be hard to study treatments for these diseases.
- Conditions
- Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors
- Trial name
- NCT06041503
- Testing
- Pembrolizumab, Enfortumab vedotin
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab
- Conditions
- Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
- Trial name
- NCT04040361
- Testing
- Pembrolizumab, Ramucirumab, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 24 people
- Sponsor
- National Cancer Center Hospital East
Non Small Cell Lung Cancer
Pembrolizumab in Elderly Patients With Advanced Lung Cancer
This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1).
- Trial name
- NCT03293680
- Testing
- Pembrolizumab
- Where
- 12 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Spanish Lung Cancer Group
Salivary Gland Carcinoma
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not…
- Trial name
- NCT03942653
- Testing
- Goserelin Acetate, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Manish Patel
Pancreatic Cancer
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline…
- Trial name
- UVA-PC-PD101 (NCT02305186)
- Testing
- Pembrolizumab, Neoadjuvant Chemoradiation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study.
- Trial name
- NCT04305054
- Testing
- Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab
- Where
- 60 sites in United States, Argentina and 12 more
- Volunteers
- 335 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
Various approaches are currently being developed for prostate cancer immunotherapy. However, a major challenge facing the development of cancer immunotherapy is the identification of tumors that would best respond to this type of…
- Trial name
- PICT-01 (NCT04009967)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- CHU de Quebec-Universite Laval
Breast Cancer, Chest Wall Disease
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
This is a phase II multicenter study including breast cancer patients with chest wall disease that is hormone resistant (estrogen receptor (ER) positive/progesterone receptor (PR) positive/human epidermal growth factor receptor 2…
- Trial name
- NCT03095352
- Testing
- Pembrolizumab, Carboplatin, Trastuzumab
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- Laura Huppert, MD, BA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.